Home / Stocks / Novartis India Limited
NOVARTIND

Novartis India Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 03 Nov 2026

₹1,722.4

Change

+4.7 (0.27%)

Open

₹1,739.0

Prev. Close

₹1,717.7

Day High

₹1,744.1

Day Low

₹1,672.5

Volume Analysis

Traded

27,268

Delivered

18,439

Delivery %

67.62%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,825.1 ₹1,784.6 ₹1,753.5 ₹1,713.0 ₹1,681.9 ₹1,641.4 ₹1,610.3
Fibonacci ₹1,784.6 ₹1,757.25 ₹1,740.35 ₹1,713.0 ₹1,685.65 ₹1,668.75 ₹1,641.4
Camarilla ₹1,742.09 ₹1,735.53 ₹1,728.96 ₹1,713.0 ₹1,715.84 ₹1,709.27 ₹1,702.71

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+0.0%

1 Month

-2.58%

3 Months

+21.39%

6 Months

+26.16%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Novartis India Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Corporate Governance (85/100), while Institutional Ownership (52/100) is the weakest area to weigh before deciding. FII holding has been rising.

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 61/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 03 Nov 2026 · How we calculate this →

Corporate Governance

85

Institutional Ownership

52

Risk & Volatility

68

Liquidity

58

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

BSE gave in-principle approval for ₹9,000 million rights issue; board meets November 4, 2026.

Q2 and half-year FY2026-27 earnings call on November 4, 2026 at 2:30 PM IST.

Mr. Gagan Sharma appointed Senior Management Personnel effective October 26, 2026.

Intimation of the Newspaper Advertisement made by the Company in Financial Express and Navshakti today i.e. October 14, 2026, w.r.t. the completion of dispatch of …

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.68% → 70.68%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 28.6% 28.61% 28.6% 28.61% 28.6% 28.61% 28.6% 28.61% 28.5% 28.6% 27.81% 26.61%
Promoters 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68% 70.68%
FII 0.19% 0.19% 0.19% 0.19% 0.19% 0.19% 0.19% 0.19% 0.19% 0.17% 0.16% 1.21%
DII 0.52% 0.52% 0.52% 0.52% 0.53% 0.53% 0.53% 0.53% 0.63% 0.53% 1.35% 1.5%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Novartis India Limited (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Novartis India Limited?

Frequently Asked Questions about Novartis India Limited

Community Sentiment

What are other investors saying about Novartis India Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.